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Glossary  
2D, 2-dimensional; 3D, 3-dimensional; ADME, Absorption, Distribution, Metabolism Excretion; ADR, 
Adverse Drug Reaction; ADRs, Adverse Drug Reactions; AE, Adverse event; AEs, Adverse events; 
APAP, acetaminophen; ATF6, Activating transcription factor 6; ATP, adenosine triphosphate; BA, bile 
acid; BAC, bacterial artificial chromosome; BC, bile canaliculi; BCRP, breast cancer resistance protein; 
Bip, Binding immunoglobulin protein; BSEP, bile salt export pump; CsA, cyclosporine A; CA, cholic 
acid; CADs, Cationic amphiphilic drugs; CDCA, chenodeoxycholate; CHOP, C/EBP homologous 
protein; ClogP, The logP value of a compound; Cmax, maximum concentration; CPT-1, carnitine 
palmitoyltransferase-1; CRM, chemically reactive metabolites; Css, Concentration at Steady State; 
CTLA-4, cytotoxic T-lymphocyte-associated protein 4; CYP, cytochrome P450; DAMPs, damage-
associated molecular patterns; DCA, deoxycholate; DIC, diclofenac; DILI, drug-induced liver injury; 
DILI-sym, drug-induced liver injury modelling software; EFPIA, European Federation of 
Pharmaceutical Industries and Associations; ENT, equilibrative nucleoside transporter; ER, 
endoplasmic reticulum; GCDCA, glycochenodeoxycholate; GFP, green fluorescent protein; Glu-Gal, 
glucose-galactose; GSH, glutathione; HCA, high-content analysis; hENT1, human endonucleoside 
transporter-1; HLA, human leukocyte antigen; HMGB1, high mobility group box protein-1; ICAM1, 
intercellular Adhesion Molecule 1; IFN-, interferon-; IL-1β, interleukin-1 β; IL-8, interleukin-8; iPS, 
induced pluripotent stem cells; IRE1α,  inositol-requiring enzyme 1 α; IVIVE, in vitro-in vivo; LCA, 
lithocholic acid; LPS, lipopolysaccharide; LSEC, liver sinusoidal endothelial cell; luc, luciferase; MATE, 
Multidrug and toxin extrusion protein; MICS, microphysiological systems; MIP-DILI, Mechanism-
Based Integrated Systems for the Prediction of Drug-Induced Liver Injury; MLC, myosin light chain; 
MLCK, myosin light chain kinase; MRP, multidrug resistance-associated protein; mtDNA, 
mitochondrial DNA; NCE, new chemical entity; NCEs, new chemical entities; NFkB, nuclear factor-
kappa B; NK, natural killer; NPCs, non-parenchymal cells; Nrf2, nuclear factor erythroid 2–related 
factor 2; NTCP, Na+-taurocholate co-transporting polypeptide; OATP, organic anion transporting 
polypeptide; OAT, Organic Anion Transporter; OCT, organic cation transporter; OST, Organic solute 
transporter; PBMC, peripheral blood mononuclear cells; PD1, Programmed cell death protein 1; 
PERK, protein kinase RNA-like endoplasmic reticulum kinase; PHH, primary human hepatocyte; 
PKPD, Pharmacokinetics & pharmacodynamics; PL, phospholipidosis ; R&D, research and 
development; RelA, REL-associated protein; ROCK, Rho kinase; ROS, reactive oxygen species; 
S100A9, S100 calcium-binding protein A9; SCHH, sandwich-cultured human hepatocyte; SOS, 
sinusoidal obstructive syndrome; SRXN1, sulfiredoxin 1; TCA, taurocholic acid; TCR, T-cell receptor; 
TK-NOG, thymidine kinase transgene incorporated into immunodeficient NOG mice; TNF-, tumor 
necrosis factor-; TRAF2, TNF receptor-associated factor 2; Tregs, regulatory T cells; VBDS, vanishing 
bile duct syndrome; UPR, unfolded protein response; XBP1, X-box binding protein 1. 
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Abstract 
Drug-induced liver injury (DILI) is a patient-specific, temporal, multifactorial pathophysiological 
process that cannot yet be recapitulated in a single in vitro model. Current pre-clinical testing regimes 
for the detection of human DILI thus remain inadequate.  A systematic and concerted research effort 
is required to address the deficiencies in current models and to present a defined approach towards 
the development of new or adapted model systems for DILI prediction. This Perspective defines the 
current status of available models and mechanistic understanding of DILI, and proposes our vision of 
a roadmap for the development of predictive preclinical models of human DILI.  
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Introduction 
Adverse drug reactions (ADRs) are a major clinical problem in terms of patient morbidity, patient 
mortality, cost to healthcare systems and failure of drugs in development.  The liver is one of the 
organs most susceptible to drug toxicity, and in the clinic, drug-induced liver injury (DILI) has 
accounted for more than 50% of acute liver failure cases1.  Excluding acetaminophen, DILI accounts 
for approximately 14% of acute liver failures with a mortality rate of up to 10%2.  DILI is also a major 
cause of drug attrition, leading to withdrawal of potentially valuable therapies, both during preclinical 
testing, clinical trials and post-marketing3,4.  Importantly, the FDA has annotated 750 drugs that have 
some degree of DILI risk5.  However, it is clear that current preclinical testing paradigms based on a 
combination of various in vitro and in vivo models are poorly predictive, at a quantitative and 
mechanistic level, of the potential of a new drug candidate to cause DILI in humans, in particular those 
drugs that show poorly defined dose-response relationships and/or human specific mechanisms of 
toxicity.  
There is an emerging body of evidence that DILI, as it occurs in humans, can be a multi-step and 
multicellular disease process with a diverse range of chemical aetiologies (Figure 1)6-8.  This means 
that prediction of all forms of DILI may be inherently intractable to simple solutions, such as single cell 
culture screening strategies. Thus, a much better understanding of the mechanisms underlying DILI is 
essential in order to a) evaluate the strengths and weaknesses of currently available test systems and 
b) inform the design and construction of new improved predictive models.  Crucially, we must define 
not only whether a test system is fit-for-purpose, but more critically “what particular purpose is a test 
system fit for”. In addition, we need to be aware of which forms of DILI we can predict and which 
forms of DILI we cannot predict, when there is no human experience with the drug. 
Given the multifactorial mechanisms of DILI, which contribute to drug attrition in development and in 
clinical practice, there is a need for new thinking in terms of the development of a holistic approach 
to the early detection of chemical liabilities which are predictive of DILI. Such an approach must be 
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mechanism-based, pragmatic and sufficiently adaptable to be of practical application to 1) influence 
drug design early enough in the discovery phase and 2) manage risk assessment in drug development, 
which is amenable to evaluation by drug regulators, but cognisant of current limitations in our 
understanding of DILI. This is particularly important when human risk factors dominate over chemical 
risk factors, e.g. for idiosyncratic drug toxicity.  
It is clear from a review of the literature, that no single system is fit-for-purpose as a universal test for 
DILI in humans, which is a patient-specific, temporal, multifactorial pathophysiological process. 
Therefore, what is required is a portfolio of robust and well-characterised predictive DILI platforms 
that have their purpose well-defined, and acceptable in a theoretical and practical sense to academic, 
industry and regulatory agencies.  
This perspective presents our vision for a DILI roadmap, with the aim of managing DILI risk and 
ultimately assisting in the design and development of safer and more effective medicines. Our 
approach is comprised of a tiered system, which integrates established and emerging cell-based 
technologies into a coherent map for drug development and, ultimately, for drug regulation.   
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Proposed DILI Roadmap  
Potential strategies to de-risk DILI in drug discovery have previously been published. These 
approaches, whether presented as in vitro hazard/liability matrices9,10 or tiered testing cascades, are 
typically those of a single institution or focus only on single mechanisms, proprietary test systems11-
14, legacy compound datasets15, and/or technology platforms16,17. For this reason, there has 
remained little or no consensus on the use or approach to de-risk DILI. Moreover, many of these 
strategies may not be readily amenable for adoption by small enterprises and start-ups where in-
house capacity and availability of proprietary compounds to validate such approaches are lacking.   
The DILI Roadmap discussed in this Perspective was established by nine medium-large EFPIA 
pharmaceutical companies, SMEs and academic partners as a holistic strategy to manage human DILI 
risk. Our approach delivers an in-depth inter-laboratory evaluation of the fundamental and 
reproducible performance of assays, to identify chemical liabilities in drug discovery and to manage 
DILI risk in development. Our roadmap (Figure 2) integrates established and emerging test systems, 
and is based on a 3-tiered approach, whereby the complexity of the model increases progressively 
from single cell 2D to multi-cell 3D systems through to systems that incorporate human individual-
specific factors, such as genetic- or disease-related factors.  
As the Roadmap incorporates assays and cell models which are well-characterized and have proven 
their utility18-20 as well as emerging novel systems with anticipated future benefit, this enables the 
versatility of the Roadmap to evolve with the advent of future qualified complex DILI models  
Cell Models  
There are numerous examples of significant interspecies differences in DILI, caused for example by 
species variations in the specificity of drug metabolism and exerted toxicity. Accordingly, human-
based in vitro systems for predicting in vivo DILI in man are preferable. The in vitro systems should 
 Page 8 of 61 
 
exert a relevant phenotype, mimicking the functionality of hepatocytes in vivo and, since many drugs 
exert a delayed DILI response, the system must exhibit long-term stability.  
Much attention has been placed on the refinement of 2D cell systems and development of a 3D 
spheroid system based largely on primary hepatocytes, where the transcriptomic, proteomic and 
metabonomic profile as well as the functionality of the spheroids are very similar to the specific donor 
liver18,21-23. Such spheroids have also been shown to imitate liver disease induced by altered 
physiological conditions24. When challenged in long-term cultures with 122 drugs with or without 
direct implication in clinical DILI, this spheroid system successfully detected 69% of all hepatotoxic 
compounds without producing any false positive results (100% specificity), thereby exceeding all 
previously published in vitro assays at substantially lower drug concentration levels, that approach 
Cmax or Css in blood with drugs known to cause human DILI23. Single cell models, whether primary or 
immortalised, nevertheless lack the intricacies of a multicellular environment, and whilst a range of 
inventive technologies have been developed to build complex 3-D structural models, none published 
so far has been able to recapitulate the complex physiology of the intact liver.  
Much effort is now being directed to develop different kinds of more physiologically-relevant in vitro 
systems such as 2D and 3D multi-cellular tissue chip and microfluidic systems which can provide a 
relevant cellular milieu for studies of liver function and DILI25,26. In addition, microfluidic 
microphysiological (organ-on-chip) systems are being built in a multi-organ fashion which in the future 
may be able to further integrate complex mechanisms relevant for the production of idiosyncratic 
human DILI27.  
However, despite significant efforts towards developing the next generation of advanced in vitro-
based liver models with greater physiological relevance, none are presently in routine use by industry. 
This in part is due to remaining technological challenges and a required demonstrable ‘paradigm shift’ 
in predictive power yet to be established28-30.  2D cell-based assays platforms therefore remain 
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common practice for screening due to their ease of use, availability and suitability for HTS28,31, despite 
their reported limitations of physiological relevance8,32.  
It may not be possible to combine all features of a fully functioning liver in microphysiological tissue-
based systems (MPS) models, thereby requiring the integration of input from more than a single test 
system. Nevertheless, there is an opportunity to capitalize on the use of established 2D cell models 
and assays in a tiered and congruent manner that applies physiological and pharmacological 
knowledge, advantages and limitations of these 2D cell models, with more advanced models as they 
become available and qualified for use. Cell-based 2D models currently comprise traditional liver 
derived cell-lines and primary hepatocytes. Features facilitating use of 2D cell models such as HepG2, 
HepaRG, and primary hepatocytes are summarized elsewhere33 and in Table 1, and represent the most 
commonly available and widely used cell models by industry. Given this, along with the breath of 
available literature on the characterization of HepG2 and HepaRG, this prioritizes the use of these cell 
models in a tiered approach for screening of key mechanisms associated with human DILI.  
In addition, the strategy described in this Perspective for assessing DILI risk encompasses the 
application of cell models most appropriate for a given mechanism being studied (sections 3-8; 
mitotoxicity, ER stress, or bile canilicular dilatation).  Hence, each individual cell model is not only 
defined as uniquely a TIER 1 or TIER 2 test, but also by the toxicological endpoint(s) under evaluation  
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Physicochemical characteristics associated with DILI risk 
High daily doses and high systemic exposures to drugs are associated with increased risk of DILI34,35. It 
is therefore important to account for the intended pharmacological drug exposure (concentration) 
and ADME data alongside the use of the in vitro DILI roadmap (Figure 2), to help integrate 
concentration-effect relationships for the prediction of DILI.  Low doses are desirable and ideally doses 
< 100 mg/day should be targeted for oral drugs36. For example, evaluation of the top 200 oral drugs 
in 2009 in the USA and of 68 drugs recalled or associated with a black box warning due to idiosyncratic 
toxicity, indicated that the major differentiating factor between the two groups of drugs was the total 
daily dose37. Likewise, the vast majority of oral drugs with reported idiosyncratic liver toxicity are 
administered at high clinical doses38.  
Not surprisingly, given their influence on efficacious doses, some physicochemical properties (e.g. 
lipophilicity, polar surface area, number of hydrogen bond donors and acceptors) have also been 
shown to be associated with an increased risk of DILI. For this reason, determining the physiochemical 
properties of a compound is important.  Computational tools are available as TIER 1 assays to guide 
early drug design by predicting physicochemical properties or sites of metabolism, metabolite 
structure, cytochrome P450 (CYP) binding/inhibition, and CYP induction39,40.  Examples include the 
Meteor program, MetaSite, and ADMET Predictor39,41,42. The links between compound characteristics 
of interest (e.g., physicochemical properties, bioactivation, and general toxicity) and molecular 
structure (i.e., ‘the similarity principle’) form the basis of these in silico applications that differ only in 
terms of complexity and performance43. For example, various toxicophores or problematic 
substructures can be identified with this approach44,45. These computational assessments are typically 
conducted prior to TIER I assays in order to prevent the synthesis of compounds with low probability 
of success or to prioritize screening of subsets of compounds, thereby optimizing drug discovery 
efforts. However, in silico tools still have some limitations and traditional “wet-lab” experimentation 
with data generation as depicted in the Roadmap as TIER 1 assays is recommended for screening of 
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compounds to confirm predicted readouts from these in silico applications (i.e., spot-checking 
exercise). Several quantitative systems toxicology platforms have been proposed to predict and 
understand DILI.  DILIsym® is an in silico approach to predict DILI based on known mechanisms46. The 
software relies on predetermined mechanisms, such as oxidative stress, glutathione metabolism, 
mitochondrial dysfunction, and ATP depletion to simulate a DILI outcome41. The DILI prediction system 
(DILIps) uses a quantitative structure-activity relationship (QSAR) approach to classify a compound’s 
propensity to induce DILI47 by use of drugs known to cause DILI. Whilst retrospective analyses of 
known hepatotoxic drugs help to identify potential hazard, quantifying risk and predictive value and 
identification of some types of DILI, such as idiosyncratic DILI in patients is not yet achievable.  The 
main points concerning the importance of dose and physicochemical properties are presented in BOX 
1 and discussed in further detail in the supplementary section.  
Intracellular perturbations associated with DILI liability  
A number of intracellular chemical perturbations elicited by pharmaceutical compounds are 
associated with a DILI liability, including mitochondrial dysfunction, inhibition of biliary efflux, 
lysosomal impairment, production of reactive metabolites, endoplasmic reticulum stress,  as well as 
involvement of the immune system (Figure 1). Below we will discuss these factors and examine how 
they can be evaluated using our tiered testing strategy as shown in the DILI roadmap (Figure 2).  
Mitochondrial dysfunction 
In a recent study of 300 drugs, 50-60 % of those that can elicit idiosyncratic toxicity cause 
mitochondrial perturbation, whereas amongst non-DILI drugs this falls to <5%48, (supplemental 
section, Figure 1). However, in many cases where hepatotoxicants have been shown to contain 
mitochondrial liabilities, there is limited clinical evidence linking this mitochondrial dysfunction to the 
onset of DILI.  
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Over the past decade the pharmaceutical industry has sought to incorporate the detection of 
compounds capable of inducing mitochondrial dysfunction into preclinical testing strategies49.  The 
mainstay of such testing stems from the recognition that the use of cells of a tumorigenic nature 
obscures detection of mitotoxicity. This is due to an altered bioenergetic phenotype which enables 
them to use glycolysis to produce ATP, not mediated via mitochondrial oxidative phosphorylation, to 
sustain continued growth and proliferation. To circumvent this, the technique of metabolic 
modification to identify compounds which contain mitochondrial liabilities was described50,51.  
Specifically, HepG2 cells are adapted to culture in either glucose- or galactose-containing media over 
a period of weeks and then exposed to compounds for 24 hours.  A rightward shift in cell death or ATP 
dose-response curves in galactose media, due to a complete dependence upon oxidative 
phosphorylation for ATP generation, provides evidence for mitochondrial dysfunction.  However, 
despite widespread adoption, the glu-gal assay has low prediction rates and subsequent work 
amended the original protocol52.  For  example, acute exposure (2-8 hours) of HepG2 cells to test 
compounds and dual assessment of cellular ATP content and cell death in cells in which the metabolic 
switch is made over 2 h53,54 enables an additional evaluation of whether mitochondrial dysfunction is 
a cause of cell death53.  Characterisation of this HepG2 model revealed its utility to detect and rank, in 
terms of potency, those compounds, parent or synthetic equivalents of any human metabolites, which 
directly induce mitochondrial dysfunction via interference with the electron transport chain.  
However, its evaluation using a larger set of compounds is still required to determine whether these 
changes result in a significant improvement in specificity and selectivity.  The simplicity and ease of 
the acute metabolic switch (glu-gal) assay when used over an acute period, in contrast to other forms 
of this assay, facilitates its use as a TIER 1 assay; i.e. to be adopted early in the preclinical testing 
strategy to rapidly screen compounds.  The principle of in vitro, metabolic modification is applicable 
to other methods of screening for mitochondrial dysfunction, in particular mitochondrial membrane 
potential, respirometry or high content analysis, which can be used as an alternative option to identify 
compounds with a mitochondrial liability. If a compound is identified as positive, the subsequent 
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investigation to confirm classification and define mechanisms can include traditional respirometry in 
isolated mitochondria or the use of a Seahorse extracellular flux analyser for membrane potential. 
These two assays allow the measurement of both oxidative phosphorylation and glycolytic function in 
real-time, in whole and permeabilised cells or isolated mitochondria53,55.  
After an initial screen of hazard identification on a large-scale, the next stage of mitochondrial testing, 
TIER 2, should take place in more complex models designed to have greater physiological relevance 
and closer relevance to clinical exposure i.e. over weeks instead of days.  This is particularly important 
as drug-induced mitochondrial dysfunction can often form part of a multi-mechanistic pathway, 
working in concert with other processes within the hepatocyte, such as biliary transport and 
xenobiotic metabolism49. Furthermore, mitochondrial toxicity often has a delayed presentation over 
several months in the clinic due to an apparent threshold effect due to the multiplicity of mitochondria 
alongside a complex array of protective and compensatory mechanisms56. In practice, this means that 
a certain amount of damage must be sustained before toxicity becomes apparent. A clear example of 
this is the induction of mitochondrial hepatotoxicity by fialuridine, which caused several deaths during 
clinical trials57-59.  Toxicity was only induced following 13 weeks of exposure due to the inhibition of 
mitochondrial DNA replication.  To replicate long-term exposure in vitro, the HepaRG model is an 
appropriate choice for TIER 2 mitotoxicity testing to assess chronic drug exposure-effect on 
mitochondrial function independent of hepatocyte cell death. Research has demonstrated that these 
cells are compatible with the metabolic modification assay under short exposure times (2 – 24 h)60. 
Furthermore, the ability of this model to detect delayed mitochondrial toxicity has been shown for a 
panel of mitotoxicants with varied mitochondrial targets, including mitochondrial DNA, mitochondrial 
protein synthesis and fatty acid oxidation61,62. Importantly, this model enabled the pathway of 
mitochondrial toxicity to be delineated at concentrations in the region of drug exposure (Cmax, Css) 
in clinical practice. The metabolic modification assay (glu-gal) has also been shown to be applicable 
for cases of delayed toxicity in the HepaRG model.  Importantly, it was able to identify fialuridine as a 
mitotoxicant after 2 weeks of exposure with subsequent mechanistic studies, performed over 4 
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weeks, confirming the mechanism of toxicity via inhibition of mitochondrial DNA replication63.  The 
use of this model to assess mitochondrial toxicity against a background of underlying liver pathology 
has also been described. In particular, steatotic HepaRG models have been developed, and used to 
evaluate the effects of steatosis on cellular bioenergetics and individual susceptibility to 
mitotoxicants61.  
TIER 2 mitotoxicity testing can also encompass 3D cell systems, such as spheroids, which represent a 
more functionally-relevant liver system64. Work to create 3D spheroids of primary human hepatocytes 
(PHH) has revealed an increased sensitivity to fialuridine over extended periods, with effects beginning 
at 7 days and increasing over 28 days of exposure21. Such studies reveal the importance of temporal 
toxicodynamic events not captured in short-term assays.  
Although TIER 1 and TIER 2 testing has developed to improve the detectability of mitotoxicants, these 
results must always be viewed as identification of chemical liabilities in the absence of quantitative 
IVIVE extrapolation and PKPD clinical readout. Traditionally, it has been difficult to bridge from in vitro 
studies to humans using animal models of mitotoxicity. Specifically, in vivo studies do not adequately 
represent the clinical situation as they are often performed in young and healthy in-bred rodent 
models which have therefore a reduced sensitivity to mitotoxicants65.  As such, TIER 3 systems for 
evaluating mitotoxicity remain less well-defined. However, one successful example was the 
susceptibility of the chimeric TK-NOG mouse with humanised liver to fialuridine-induced 
hepatotoxicity, at doses approximately ten times the therapeutic exposure, which presented with 
clinical and pathological features in line with the DILI observed in humans66.  
It is clear that the current DILI roadmap for mitotoxicity testing can identify certain mitochondrial 
liabilities.  However, there is still no clear path to predicting potential risk in patients.  In silico 
modelling is beginning to provide systems with which to bridge this translation by taking into account 
patient-specific factors, for example, individual health or disease state, in order to assess impact on 
mitochondrial toxicity. One example of such modelling is found in DILI-sym®, i.e. mitoSYM®, which has 
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been developed to aid the mechanistic understanding of clinical hepatotoxicity and was used 
successfully to determine retrospectively the role of mitochondria in tolvaptan hepatotoxicity and 
most recently macrolide antibiotics and TAK-87567-70. Overall, the last 10 years have seen significant 
advances in the development of models and test systems to identify mitochondrial toxicity. Practically, 
it is recommended that they are deployed in preclinical safety testing in a step-wise approach; TIER 1 
is suitable for the risk assessment of many compounds, whilst TIER 2 and subsequent mechanistic 
work incorporating temporal toxicodynamic events can be used to follow-up on selected compounds 
of interest. TIER 3 remains a work in progress which is continuing to develop as the fundamental 
mechanisms directing inter-individual variation and species selectivity are discovered. Until such 
further progress is made, TIER 3 can function as an opportunity to retrospectively assign mechanisms 
and understand at-risk populations once clinical signals of hepatotoxicity have been observed.  
Energy metabolism and in particular, mitochondria respiration are key processes in the build-up of 
fatty liver deposits as the site of fatty acid oxidation, and many of the drugs known to interact with 
the mitochondria at the level of β-oxidation, electron transport chain or mtDNA are associated with 
hepatic steatosis71. Drugs implicated in hepatic steatosis affecting the electron transport chain (ETC) 
and β-oxidation of fatty acids is metabolically linked, such that drugs affecting ETC pathway invariably 
inhibit β-oxidation. The rate-limiting step for fatty acid oxidation is the mitochondrial carnitine-
palmitoyl transferase-1 system; when mitochondrial β-oxidation is severely inhibited, fatty acyl-CoA 
β-oxidation is impaired with increased fatty acyl-CoA and fatty acids. These fatty acids are converted 
into triglycerides that are believed to be hepato-protective mechanisms of importance in 
mitochondrial toxicity72.  Further details on the assessment and mechanisms of steatosis and 
detection thereof are provided in section 3 of the supplementary information.  
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Transporters in drug- and bile acid (BA)- induced liver injury  
Drug-induced cholestatic liver disorders are among the most severe clinical manifestations of human 
DILI and account for almost half of the cases of drug-related hepatotoxicity73,74. These liver disorders 
are broad, yet are characterized by acute and chronic impaired hepatocellular secretion of bile, with 
accumulation of systemic BAs and their bile salts, bilirubin and cholesterol (Supplementary 
information).    
In many cases, the disruption of BA secretion results from functional changes in the hepatobiliary 
transporter system. These membrane transporters facilitate uptake and efflux of endogenous 
substances and drugs between the basolateral, sinusoidal and apical (bile canalicular) membranes of 
the hepatocyte. Many drugs are also identified as inhibitors of these membrane transporters (Figure 
3). The localization of membrane transporters, expression of family and sub-family members, and 
polarity of transporter proteins convey the highly-regulated physiological and pharmacological role in 
the hepatobiliary transport of BAs (supplemental text). 
Many drugs inhibit the biliary excretion of conjugated bile salts, mediated by BSEP75. Trafficking of 
intracellular pools of membrane transporters, such as BSEP, can be swiftly recruited and inserted into 
membranes as a result of drugs or increases of intracellular BAs.  BSEP inhibition studies have been 
proposed for the assessment of human DILI and the cholestatic potential of drugs76-78. These inhibition 
studies are often implemented as non-cell-based screening TIER 1 assays to rank compounds that 
inhibit BSEP alongside other hepatobiliary transporters. Nevertheless, there are false positives and 
false negatives identified when solely screening for liabilities associated with BSEP inhibition77,78, as 
not all cholestatic drugs inhibit BSEP and detection of BSEP inhibition will be dependent to some 
extent on the methodologies and test systems employed31. A further complexity are drugs (e.g. 
captopril and cimetidine) known to cause cholestasis without apparent interaction with BA 
transporters79 or transporters associated with BA-independent flow. Therefore, correct classification 
of drugs on the basis of liver-induced severity may also explain some conflicting results. Using the FDA 
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DILI severity assessment, published BSEP inhibition datasets were recently re-examined, and it was 
concluded that the inverted vesicle assay is not predictive of the toxic potential of drugs80.   
Inverse membrane vesicles expressing human transporters allow us to detect only direct interactions 
with drugs. The influence of cellular factors that can be critical in the occurrence of DILI can be 
investigated only with polarized functional hepatocytes as part of a TIER 1 testing strategy. Sandwich-
cultured human hepatocytes have been widely used to evaluate BA disposition; indeed over time in 
sandwich configuration, hepatocytes develop functional bile canalicular networks and express hepatic 
transport proteins on the correct membrane domains. This cell model has served widely for studies 
on drug-induced alterations of BA disposition using taurocholate as a model BA. Effects of drugs on 
canalicular versus basolateral efflux, measurements on BA accumulation in cells and bile canaliculi 
versus medium have been extensively analyzed81-86. However, published data sets are scarce. The 
sandwich-cultured human hepatocyte model has allowed a better separation of BSEP inhibitors 
associated with severe DILI (e.g. cyclosporine, ritonavir, troglitazone) from those with no DILI or mild 
DILI (e.g. rifampicin)78.  Despite many studies to try and relate BSEP inhibition and DILI, there is a 
recognized lack of causality between drug exposure and BSEP inhibition and human DILI87. 
A fraction of bile canaliculi (BC) appear irregularly dilated with conspicuous alterations of microvilli in 
cholestatic liver88. Cultured PHH and HepaRG hepatocytes exhibit an early response to cholestatic 
drugs by the deregulation of bile canaliculi dynamics through the Rho-kinase and Myosin Light Chain 
kinase kinase (MLCk) kinase pathways, with or without inhibition of BSEP and NTCP activities89. These 
effects of deregulation of bile canaliculi dynamics occur through the constriction or dilatation of bile 
canaliculi associated with actin cytoskeleton disruption, and the extent of these effects are time- and 
drug concentration-dependent. These features further support the secondary effects of enhanced 
basolateral excretion of BAs and down-regulation of genes related to bile transport, synthesis and 
detoxification90,91.   
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Early BC deformation associated with deregulation of the Rho-kinase and MLCK pathways appear to 
represent common features induced by cholestatic drugs. Importantly, a causal relationship between 
drug exposure and BC deregulation appears evident for drugs with known clinical cholestatic or rare 
cases of cholestatic potential in human.  Drugs recognized as cholestatic or involved in only rare cases 
of clinical cholestasis were found to cause dilatation or constriction of BC8,20,92. An additional drug, i.e. 
macitentan, which possesses a similar chemical structure to bosentan was also classified as 
cholestatic8. It is noteworthy that the first case of acute liver failure associated with macitentan 
treatment was only recently reported, and that histology revealed chronic hepatitis associated with a 
process of micronodular cholestatic cirrhosis93. 
Little information exists on the early changes in BA total content and profiles in human liver exposed 
to cholestatic drugs. Hydrophobic BAs are much less hepatotoxic in humans than in various animal 
species85,94. Accordingly, GCDCA and LCA were found to be cytotoxic in in vitro only at very high 
concentrations85,95.  PHH and HepaRG hepatocytes synthesize, conjugate and secrete BAs in vitro95,96. 
However, only transient cellular accumulation (if any) can be detected in hepatocytes cultured in a 
serum-free medium.  BA production is too low and in addition, synthesis and efflux can be inhibited 
and compensatory secretion via the sinusoidal transporters MRP3/4 activated by cholestatic drugs97.  
In fact, the cells have to be incubated with exogenous BAs at physiological or higher serum 
concentrations to observe any cellular accumulation of BAs. In such conditions, cellular accumulation 
of unconjugated CDCA and DCA and their conjugates, as well as of LCA and sulfated LCA and to a lesser 
extent unconjugated CA and its conjugates, can be observed with cholestatic compounds after 24h 
treatment at non-cytotoxic concentrations92,98. These results support the likelihood of an inhibition of 
BA conjugation and sulphation activities; they also indicate that cellular accumulation of BAs rapidly 
follows impairment of BC dynamics and that LCA, the most lipophilic BA, is the first to accumulate 
within hepatocytes after addition of cholestatic drugs. Together with BC dynamics, the impairment of 
cellular accumulation of hydrophobic BAs could represent potent biomarkers of the cholestatic 
potential of new compounds92 and form part of a TIER 1 testing strategy to confirm results from non-
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cell-based transport inhibition screening studies. Another method that has been developed for the 
evaluation of the cholestatic potential of drugs is based on the inhibition of urea production in 
sandwich-cultured human hepatocytes co-exposed to drugs and an exogenous BA mixture99. 
Compared to the preceding method that measures cellular accumulation of toxic BAs, this drug-
induced cholestatic index likely reflects BA-enhanced cellular toxicity of cholestatic drugs rather than 
changes in BA secretion and formation. In addition, 3D PHH spheroids have been used for predicting 
drug-induced changes in BA transport and hepatocellular toxicity. Highest sensitivity is seen during 
prolonged incubation time of the spheroids in the presence of exogenous BAs and the drug and 
sensitivity might be somewhat improved100,101.  
The difficulties in interpreting transporter data using inverted membrane vesicles clearly warrants 
confirmatory studies by the use of well-characterized phenotypically-stable cell models. Sandwich-
cultured PHH and HepaRG hepatocytes currently appear to be the most appropriate cell models for a 
TIER 1 test system. They possess both physiological and anatomical features of the native hepatocyte 
with correctly polarized transport proteins and bile canaliculi. Of the two cell models, HepaRG 
hepatocytes are easier to handle and functionally relatively stable over several weeks in 2-D 
configuration102. Both models can serve as a priori TIER 1 assays for early hazard identification of drugs 
to cause acute and even chronic changes in BA transport and secretion processes. 3-D cultures can 
also be obtained with PHH and HepaRG cells, and may serve as TIER 2 confirmatory test systems. In 
general, functions are better preserved over several weeks and co-cultures with other hepatic or non-
hepatic cells can be performed. Recently, 3-D models of cholangiocytes have also been developed; 
they could be used to analyze extrahepatic mechanisms of toxicity induced by some compounds that 
cause damage to bile ducts103. 
Of the TIER 1 cell-based models for the study of in situ hepatobiliary transporters, only cell-lines are 
readily amenable to HCA screens due to matrices required for PHH to maintain cell 
differentiation90,91,104-106 and subsequently existing methodologies for PHH are low-throughput. 
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Robust quantifiable readouts required for ranking sets of compounds by use of transporter-selective 
probe substrates are not yet available. Most importantly, 2D PHH models do not permit time-resolved 
studies over extended treatment periods of several days to assess delayed onset of drug treatment 
without underlying changes in the constitutive phenotypic expression of DMEs and transporters. 
Opportunities for the use of advanced cell-based TIER 2 assays for the study of ‘long-term/chronic’ 
drug treatment on transporter function, BAs and on multiple indirect and direct targets should be 
more fully explored. For example, CsA and chlorpromazine exhibit concentration-dependent effects 
on mitochondrial membrane permeability and ER stress, respectively, which in turn may have longer-
term implications on hepatobiliary transporter function. Advanced TIER 2 models, with incorporation 
of NPCs, would also permit more comprehensive mechanistic studies on the role of innate immune 
function in the initiation, adaptation and progression of changes in hepatobiliary transport function 
and BA secretion by drugs; the association between indirect and direct effects on the role of 
transporters on BAs secretion and transport, and role of the immune system are well-described107,108. 
Furthermore, technological advances in the development of in vitro models to explore the role of 
innate and adaptive immunity (TIER 3) in cholestasis is still required and remains an important focus 
for future research efforts to understand human DILI.  
Lysosomal perturbation  
Drug-induced phospholipidosis (PL) is the accumulation of phospholipids in cells, characterized by 
lamellated, membranous deposits in lysosomes. The accumulation of phospholipids can occur in any 
tissue, is often first observed as lung “foamy macrophages” in pre-clinical studies, and is confirmed 
ultrastructurally. Cationic amphiphilic drugs (CADs), such as amiodarone, perhexilene, and 
chlorphentermine, are typical molecular structures associated with PL. Lysosomal trapping is the 
mechanism by which CADs accumulate109. CADs are neutrally-charged when crossing the lysosomal 
membrane, but become positively charged in the acidic lysosomal compartment and thus, less 
membrane permeable. Once trapped in lysosomes, CADs may directly inhibit phospholipase activity 
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leading to reduced ability to process phospholipids, or bind to phospholipids, resulting in a large 
complex that cannot be metabolized or processed110.  
In the context of DILI, the consequences of PL remain the subject of debate. Some association between 
DILI and PL has been proposed for drugs like amiodarone and perhexilene maleate111; however, the 
literature and supporting data are not very clear, not confirmatory of a real association, and suggest 
that the primary mechanism of toxicity is more related to mitochondrial dysfunction, disrupted ATP 
production and fatty acid catabolism.  For example, perhexilene is a carnitine palmitoyltransferase-1 
(CPT-1) inhibitor with multiple effects on mitochondrial function and in vivo evidence of fatty acid 
metabolism inhibition112.  This mechanism is more consistent with the histopathological appearance 
of the DILI cases that have been called “pseudo-alcoholic hepatitis,” rather than a classic case of 
phospholipidosis. Likewise, the histologic appearance of amiodarone DILI cases suggests that PL is an 
independent and non-related phenomenon113. Other hypotheses have suggested that PL is a novel 
protective mechanism of the cell, in which CADs are sequestered in the lysosomes preventing their 
migration and damage to critical organelles114. 
In general, the pharmaceutical discovery strategy is to lessen the propensity of candidates to induce 
PL. However, in the absence of other issues or toxicity, PL has not been necessarily considered a signal 
sufficient to halt drug development. To optimize compounds toward reduced PL propensity, various 
in silico tools can be used to complement a TIER I approach complemented or not by in vitro assays 
(e.g. LipidTox assay) or high content screening approaches to identify general PL risk, often using a 
standard CAD as a reference control (e.g. amiodarone)115,116; these activities can often be timed with 
the characterisation of the physicochemical properties of compounds described in section 3. If PL 
remains a concern, then it will be necessary to determine if PL occurs in vivo and at what exposure 
along with the identification of target organs (e.g. liver PL may present less risk than neuronal or retina 
PL) and concurrent histopathology and ultrastructural changes. Since in vitro and in silico assays have 
some good predictive value in terms of risk identification but are limited in terms of risk assessment, 
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the primary objectives of an in vivo evaluation are to establish a better understanding of the safety 
margins associated with PL (and consequently, good estimates of systemic exposures are required) 
and the nature of the target tissues which will determine the level of risk.  These in vivo studies are 
typically first conducted routinely for practical reasons and since the type of molecules associated with 
PL usually have a high volume of distribution, dosing for more than a week is preferable. In addition 
to traditional histopathology evaluation, special immunohistochemical methods and biomarkers may 
be used to strengthen the assessment117,118. Determining reversibility of PL in toxicology studies and 
developing a strategy for clinical monitoring may be warranted in some situations. 
Reactive metabolites and oxidative stress  
Numerous experimental and clinical investigations have demonstrated that chemically reactive 
metabolites (CRM) are produced during the biotransformation of many pharmaceuticals, including 
those linked with DILI in patients7,15,119,120. The microsomal CYPs are dominant hepatic catalysts of drug 
bioactivation and responsible for the transformations of the many drugs developed before limiting 
bioactivation became a major objective of medicinal chemistry119,121,122.  Whilst this strategy has not 
guaranteed safety for all newly-developed drugs, it has reduced the chemical liability of molecules 
with respect to DILI. Nevertheless, there remain complex challenges of managing CRM in the 
development of safe drugs, as exemplified by the case of fasiglifam (TAK-875) which was withdrawn 
from a Phase III clinical trial due to hepatotoxicity that has since been linked to protein adduction by 
a reactive acyl glucuronide metabolite123. As the role of CRM in DILI has been reviewed 
extensively121,122,124, it will not be detailed again here.  
A biochemical perturbation commonly associated with, but also known to occur in the absence of, 
CRM formation (for example, as a consequence of mitochondrial impairment) is oxidative stress, the 
excessive cellular generation of reactive oxygen species (ROS) and other organic radicals that has been 
associated with a DILI liability125,126. Oxidative stress is typically determined through the direct 
quantification of ROS, assessment of the deleterious cellular consequences of ROS accumulation (i.e. 
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lipid peroxidation, glutathione depletion) or the evaluation of key adaptive responses (i.e. increased 
activity of the Nrf2 stress response pathway). In the former case, there is evidence of inadequate 
specificity, risking misplaced biochemical perceptions, when using some of the older and 
technologically less demanding ROS assays127-129, thereby promoting an unproductive proliferation of 
reports of oxidative stress. It is likely that the fundamental understanding of a ‘probe’ compound’s 
chemistry can deliver a much more accurate assay of a ROS130 as well as more accurate biochemical 
understanding, leading ultimately to more accurate assessments of biological risk. Such considerations 
are important when probes are included in high content screening assays using simple cell models in 
TIER 1.  
Whilst activation of the Nrf2 stress response can be determined by measuring changes in the 
expression level of the transcription factor and/or its conserved target genes (e.g. sulfiredoxin 1; 
SRXN1) in standard cell platforms, such analyses are generally more suited to low-throughput, 
endpoint studies. To overcome this limitation, HepG2 cells have been genetically engineered to 
express GFP-tagged SRXN1 and other stress response markers, thereby enabling quantitative 
assessment of the dynamics of the Nrf2 response in real-time using automated live cell imaging131,132. 
This platform represents a TIER 1 test system within the DILI roadmap (Figure 1), but could in principle 
be adapted to more complex models including 3D/spheroid cultures for use in Tier 2, where metabolic 
relevance is enhanced, as has been shown for HepG2 cultured in 3D133.  In TIER 3, the transgenic Nrf2-
luc reporter mouse134 has shown promise for detection of the Nrf2 response to drug-induced oxidative 
stress at the whole body level135. Using real-time bioluminescence imaging, localised signals were 
detected in the liver (acetaminophen) and kidneys (cisplatin) in vivo and ex vivo, consistent with 
immunohistochemical analysis that showed an elevated expression of luciferase in centrilobular  
hepatocytes and in tubular epithelial cells, respectively. As a low-throughput in vivo test system, 
the Nrf2-luc reporter mouse could be employed in bespoke mechanistic investigations (TIER 3) at 
later stages in preclinical drug development. In a tightly-focussed in vivo experiment, this would 
indicate tissue-selectivity and temporal dynamics of the physiological response to oxidative stress 
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in a fully metabolically-competent model – this is relevant for human translation as it will allow a 
better association with dose and PK, also enabling repeat dosing and monitoring of adaptation.  
Acetaminophen is typically considered to be the paradigm compound for the study of CRM and 
oxidative stress in hepatotoxicity136.  It is well-established that cytochrome P450 (CYP)-mediated 
bioactivation of acetaminophen to the CRM N-acetyl-p-benzoquinoneimine results in the depletion of 
hepatic glutathione and the consequent accumulation of ROS and covalent modification of numerous 
protein targets.  From the clinical perspective, it is interesting to note that delayed idiosyncratic DILI 
for acetaminophen has not been described, despite the fact that thousands of people take it daily for 
osteoarthritis. In the context of the DILI roadmap (Figure 2), it is important to note that simple cell 
systems such as HepG2 generally lack metabolic competence and are therefore largely incapable of 
reflecting the mechanisms underlying acetaminophen hepatotoxicity in vivo (extensively reviewed 
in137), although genetic manipulation of cells to restore expression of selected CYP enzymes has been 
shown to improve sensitivity to acetaminophen and other selected hepatotoxicants11. In the future, 
as more CRM-forming drugs become eliminated from preclinical programs121, the metabolic 
deficiencies of simple cell systems could become less of a hindrance in early drug safety testing. 
Experimental confirmation of the value of a test system for examining the toxicity associated with 
acetaminophen and similar compounds can be gained by assessing the impact of CYP inhibition (e.g. 
with 1-aminobenzotriazole) on drug-induced changes in pertinent cellular readouts. For example, such 
an intervention was found to ameliorate the hepatotoxicity and localised reporter signal in 
acetaminophen-treated Nrf2-luc mice135, which is consistent with the role of CRM formation and 
oxidative stress in the activation of the Nrf2 stress response in this setting. 
Beyond acetaminophen, a key question that remains to be addressed is whether other drugs are 
capable of inducing toxicologically-relevant oxidative stress in human, considering differences in daily 
dose (acetaminophen dosing is up to 4 g per day, newer drugs are typically administered < 100 mg per 
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day) and the very high concentration of the hepatic glutathione pool (5-10 mM) that must be depleted 
in order to allow CRM and/or ROS to accumulate to toxic levels.  
Endoplasmic reticulum stress  
Direct hepatotoxic drugs can induce oxidative stress in different organelles, such as endoplasmic 
reticulum (ER), leading to necrosis or apoptosis.  Such stress will induce adaptive stress response 
pathways, including the ER unfolded protein response (UPR), which is initiated by three ER 
transmembrane proteins: IRE1α, PERK, and ATF6138. Under physiological conditions, the unfolded 
proteins accumulated in the ER can activate these three signalling proteins either through the ER-
resident chaperone Bip or through direct binding to them. The activation of these proteins is 
important to restore ER homeostasis by increasing expression of ER chaperones and antioxidant 
response through the Nrf2 pathway, decreasing mRNA translation, and enhancing degradation of 
misfolded proteins139,140. When the activation of the UPR fails to protect survival, the cell actively 
pursues the proapoptotic pathway, ultimately leading to apoptotic cell death, inflammation and/or 
fat accumulation. This includes hyperactivation of protein kinase R-like ER kinase (PERK)/ATF6 
mediated activation of C/EBP homologous protein (CHOP), IRE1-mediated activation of TRAF2, and 
increased Ca2+ release from the ER141. The precise point at which this shift from adaptation to 
apoptosis occurs is not certain but clearly is influenced by the degree and the duration of the ER stress.  
ER stress has been associated with various drug-induced liver lesions and recently a clear link between 
ER stress pathway activation and drug-induced cholestasis has been reported92, where penicillinase-
resistant antibiotics (flucloxacillin, cloxacillin and nafcillin) caused early cholestatic effects through the 
induction of ER stress. 
The exact cause and effect relationship between ER stress and the mechanism of induced cell injury 
remains unclear. There appears to be a complex interplay between ER stress, conditions that promote 
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it, and those that result from it, giving rise to a cycle in which ER stress can eventually promote 
inflammation, cell injury and steatosis, all of which can (subsequently) exacerbate ER stress142.  
Wink et al131 have recently established a robust high-throughput imaging-based platform for the 
single-cell assessment of adaptive stress response pathway activation, based on a specific BAC-GFP 
HepG2 reporter cell line reflecting ER stress / UPR response pathways (specific biomarkers – XBP1, 
ATF4, BiP and CHOP). These UPR reporters have been applied together with above-mentioned Nrf2 
pathway reporters to evaluate these reporter systems against a panel of >100 DILI compounds with 
different DILI risk132.  
The immune system in DILI  
Immune-mediated DILI is rare and the mechanism of tissue injury is believed to be a complex multi-
cellular event. There is currently no screening strategy that can detect and eliminate candidates that 
may cause immune-mediated DILI.  Below,  we will review the evidence that implicates the innate 
(non-specific) and adaptive (antigen-specific) immune system in DILI at the chemical and cellular level, 
and critically assess what test systems might eventually be used for predicting hazard of NCEs using 
the DILI roadmap.  
Detection of drug-specific T-cells in patients with DILI 
The adaptive immune system has been implicated in DILI when there is a delayed onset. Histological 
investigation of liver from a patient with idiosyncratic DILI revealed an accumulation of granzyme B-
secreting T-lymphocytes alongside apoptotic hepatocytes, suggesting that T-lymphocytes participate 
in the adverse event143. Moreover, it has been possible to isolate drug-specific T-cells from PBMC of 
patients with DILI, but not drug-exposed tolerant controls. Using the lymphocyte transformation test 
it was possible to detect drug-responsive lymphocyte responses in approximately 50% of patients with 
DILI144.  Furthermore, the lymphocyte transformation test was reported to be positive in 95% of 
isoniazid DILI cases, whereas lymphocyte responses were not detected in patients receiving isoniazid 
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without evidence of liver damage145. Cloning T-cells from patients with isoniazid-induced DILI 
identified CD4+ T-cells that release an array of cytokines following drug stimulation146.  A range of anti-
drug and autoantibodies have been identified in patients with isoniazid-induced DILI147, but not 
detected in tolerant patients. In recent years, flucloxacillin-, amoxicillin- and clavulanic acid-responsive 
T-cells were isolated from patients with DILI and characterized in terms of cellular phenotype and 
mechanisms of drug antigen presentation148-150. When activated with the drug, the flucloxacillin-
specific T-cells killed hepatocyte-like cells expressing the relevant HLA allele in an in vitro model151. 
These studies are clearly beginning to define an immune basis for DILI. 
For an increasing number of DILI drugs (e.g., flucloxacillin152, augmentin153, lumiracoxib154, lapatinib155, 
ximelagatran156, isoniazid157, ticlopidine158, minocycline159, terbinafine160), genome-wide association 
studies have detected specific HLA alleles as important susceptibility factors. These data suggest that 
a highly restricted drug-derived antigen interacts with the HLA molecule to activate T-cells in 
susceptible patients. In fact, activation of flucloxacillin-responsive CD8+ T-cells from patients with 
flucloxacillin-induced liver injury has been shown to be HLA-B*57:01-restricted, which links the 
genetic association to the tissue injury148,151. 
However, it should also be noted that the majority of individuals who carry HLA risk alleles do not 
develop DILI when exposed to the culprit drug, and for most HLA-associated DILI drugs, many patients 
that develop DILI will not carry the risk allele.  
For this reason, although HLA associations represent strong evidence for an adaptive drug-specific 
immune response, they are not unqualified indicators of risk.  There is a need to characterize the 
chemical (e.g., drug-modified peptides naturally eluted from HLA molecules) and immunological 
parameters (e.g., immune regulation) that are superimposed onto the HLA association and HLA-
restricted T-cell activation to determine why specific individuals develop DILI.  
 Page 28 of 61 
 
Two hypotheses that are pertinent to the development of test systems for the assessment of new 
drugs are (1) liver injury inducing drugs activate innate signalling, and hence provide the surge of co-
stimulatory signalling and a cytokine environment rich in inflammatory mediators, to promote the 
drug-specific T-lymphocyte response and (2) susceptibility relates to dysregulated expression and 
activity of immune regulatory pathways (cell surface receptors, Tregs, cytokines, and innate cells, 
including NK T-cells, neutrophils, macrophages), which are influenced by the host’s genetic makeup 
alongside disease and environmental factors (including infections, diet, co-exposure to other drugs). 
Figure 4 summarizes our current understanding of the role of the adaptive immune system in drug-
induced liver injury, focussing on flucloxacillin reactions as a model form of HLA allele-associated 
immunological DILI.  
Involvement of innate and adaptive immune system in animal DILI models 
A limited number of animal studies show DILI involves dysregulation of innate or adaptive components 
of the immune system. In some cases, additional factors are required for liver injury to develop. These 
include microbial factors (i.e. LPS) or cytokines (in particular TNF-161,162). This has been demonstrated 
with amiodiarone161, trovafloxacin162, diclofenac163,164 and chlorpromazine. Of these animal models, 
the trovafloxacin-model is the most extensively studied. However, the onset of DILI is rapid and thus 
does not mimic immunological DILI in humans. Trovafloxacin causes cellular stress and apoptosis, 
while TNF- induces the influx and activation of monocytes and neutrophils in response to tissue 
damage162,165. Recent studies on the induction of DILI with amodiaquine demonstrated an important 
role for immunoregulatory T cells in conjunction with other cells, e.g. CD4, CD8 and NK1.1 cells. After 
3-4 weeks of oral exposure mice developed mild DILI, which resolved after 6 weeks, possibly due to 
PD1+ regulatory T cells and also damage-controlling macrophages. Indeed, immune tolerance-
breaking conditions (anti-CTLA4 in PD-1-negative mice) worsened the condition and prevented 
resolution of liver injury166-168.  Whilst the documented studies do not currently describe a widely 
applicable animal model for prediction of DILI, they do illustrate our limited knowledge of the complex 
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roles the innate and adaptive immune systems play in DILI. The main reason animal models cannot be 
used as a surrogate for human immunological drug reactions is that they do not contain fully 
integrated human innate and adaptive immune function. In the most recent advance in this field,  HLA-
B*57:01-transgenic mice were generated to study HLA-linked skin reactions and a single compound, 
abacavir, was demonstrated to activate CD8+ T cells and induce inflammation in the skin when 
regulatory pathways were perturbed169. Despite this, the tissue injury did not mimic that seen in 
humans. It is possible to consider the use of mice with humanized livers for toxicity testing purposes; 
however, such models have disrupted immune systems and therefore have limited application for 
immunological drug reactions that target liver.  There is therefore a need to study human DILI in 
physiologically- and immunologically- relevant models using human cells, and focussing on the 
parameters that have been defined in patients (HLA, TCR, immune regulatory pathways). 
There have been attempts to enhance the relevance of hepatocyte cell lines and co-culture systems 
with hepatocytes and macrophage-like cells using three-dimensional culture170. Drugs such as sulindac 
sulphide, chlorpromazine, diclofenac, and trovafloxacin have been shown to synergize with the 
cytokines TNF- and IFN- to kill hepatocytes in single cell culture162,171-173, indicating that it might be 
possible to develop relatively simple TIER 1 systems to explore innate immune signalling and drug-
induced hepatocyte death. Monocyte-derived hepatocyte-like cells from DILI patients have been used 
for causality assessment of drug-specific immune-mediated reactions174, in which in vitro toxicity 
testing revealed that DILI patient cells are more susceptible to culprit drugs. It will be interesting to 
see whether this approach can be applied to a pre-clinical setting.  
In vitro culture systems to explore the role of the immune system in DILI 
In order to improve the predictability of DILI risk using in vitro assays, a new cell-based assay evaluating 
immune and inflammatory gene expression has been developed175. The human HepaRG or HepG2 cell 
lines were exposed to 96 compounds and supernatants were then incubated with human 
promyelocytic neutrophil-derived cells (HL-60), followed by the evaluation of immune and 
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inflammatory genes. Using a combined score of S100 calcium-binding protein A9 (S100A9), IL-1β and 
IL-8 gene expression, the authors classified test compounds as DILI-positive and DILI-negative. To 
progress this assay towards a predictive test for NCEs, human drug exposure levels must be considered 
and whether inflammatory signals from HL-60 cells are an accurate marker for human DILI must be 
determined. More recently, freshly-isolated PHH have been used to characterise drug-specific 
signalling between the liver and innate immune cells176. Drug-treated PHH released damage 
associated molecular patterns, particularly HMGB1, in a drug- and dose-dependent manner. 
Furthermore, hepatocyte-conditioned media stimulated dendritic cells to secrete pro-inflammatory 
cytokines. However, the construction of in vitro systems to study the interface between the immune 
system and parenchymal cells is beset by a number of theoretical and practical obstacles. 
Transcriptomic analysis177 has revealed that freshly-isolated hepatocytes closely resemble “damaged” 
hepatocytes, which is perhaps not surprising given the conversion of intact tissue into a suspension of 
free cells. The theoretical concern is that such “damage” may inadvertently result in an undefined 
“danger signal”178 that will trigger the innate response in an uncontrolled fashion. This represents an 
important challenge for the engineering of organ-on-chip models which must be constructed from 
materials that are inert with respect to immunological activation.  Ultimately, this is one of the reasons 
why relatively long-term 3-D hepatocyte culture21 hold promise in this area, along with iPS or adult 
stem cells179-184 for differentiation towards hepatocytes, hepatic stellate cells and cholangiocytes as 
well as hepatic organoids, once these models are proven to exhibit sufficient maturity.  As an 
important aside, the conventional inclusion of supraphysiological concentrations of steroids in 
hepatocyte media may dampen immune responses, and this needs to be considered carefully when 
conducting any hepatic cell-based assays. 
To study the cellular mechanisms of immune-mediated DILI in vitro, an HLA-typed PBMC bank from 
1200 healthy volunteers has been established185. Furthermore, a cell culture method to assess the 
immunogenicity of drugs has been developed and used to explore primary T-cell responses to DILI 
drugs and the additional immunological parameters that determine whether formation of drug-
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protein adducts will result in an antigen-specific T-cell response186-189. Since cross-talk between 
hepatocytes and immune cells is likely to be critical in determining the outcome of drug exposure, it 
will be necessary to develop a co-culture system using immune and iPS-derived hepatocyte-like cells 
from the same donors with which to begin to explore the antigenic and polarizing signals released 
from hepatocytes, T-cell activation and whether the activated T-cells kill hepatocytes.   
In the context of the DILI roadmap (Figure 2), efforts are made to minimize exposure to chemical 
liabilities without biological evaluation (see section 3).  This is of importance as reactive species bind 
covalently to selective proteins generating neo-antigens for the immune system. However, this form 
of assessment alone overestimates risk as many compounds that form chemical liabilities are not 
associated with human DILI. Furthermore, compounds such as abacavir and allopurinol that activate 
T-cells through unique pathways would give false negatives in screening assays for chemical liabilities 
or covalent binding. TIER 2 systems based on 2D or 3D microtissues consisting of liver and dendritic 
cells could be used to explore whether hepatocytes deliver drug metabolites and/or tissue-derived 
signals that result in dendritic cell activation or polarization. However, co-culture systems for 
screening compounds in discovery are not routinely applied for use in drug candidate screening,  
possibly due to the lack of guidance on how to handle the results and relate them to decision-making 
or the clinical situation. TIER 3 systems are proposed to explore drug-specific T-cell and antibody 
responses.  A diagnostic toolbox of assays (e.g. lymphocyte proliferation assay, cytokine release assay, 
generation and characterization of antigen-specific T-cell clones) is now available to study human DILI 
when AEs are identified in clinical trials or when a new drug enters widespread use.  Furthermore, T-
cell priming assays with PBMC from HLA-typed healthy donors can be used as a retrospective 
investigative tool to study mechanisms of T-cell activation and to explore immunological liability of 
structurally-related compounds when a reaction has been seen in patients186,187,190. However, there is 
currently no test system available to the non-clinical scientist at present that predicts ab initio the 
likelihood that a compound, which is clearly tolerated by 99.9% of the human population, will induce 
immune responses in patients. For this reason, there is no signal identified in Phase I or Phase II 
 Page 32 of 61 
 
studies, or animal models which are intrinsically less heterogeneous with respect to human variables 
so far discovered for idiosyncratic toxicity, such as the HLA immune system. Nevertheless, we can 
clearly reduce some of the overall risk by eliminating compounds with particular DILI mechanisms in 
reproducible and well-defined models as described.  
Outlook 
The development of predictive models of DILI has been driven by the complementary imperatives of 
the pharmaceutical Industry and academic research. Industry requires serviceable predictive models, 
suitable for routine use in the support of drug candidate selection and decision-making that can aid a 
deeper understanding of the various factors that culminate in the manifestation of toxicity and can be 
confidently used to translate to the patient setting.  
From a general perspective, whilst single cell model systems are invaluable within the tiered screening 
process, it is unlikely in the short-term that any single system is able to incorporate physiologically-
relevant aspects of all of the mechanisms of DILI that have been described in the clinic and thereby 
demonstrate genuine predictive clinical safety of new drugs. At the same time, novel complex model 
systems are being used largely to further our understanding of the mechanisms involved in DILI.  
The DILI roadmap (Figure 2) proposed in this perspective has therefore been developed as a guide for 
early drug safety evaluation, and the selection of particular test systems, with careful reference to 
their pharmacological and physiological relevance to the new chemical entity under consideration, 
before use for any toxicological investigation. Since no single currently-used model is able to 
recapitulate all of the mechanisms of human DILI, we believe that there exists a need for a systematic 
tiered approach, in which model systems of increasing biological complexity can be utilised efficiently 
and effectively at different points, and on different scales, in the drug discovery and development 
process. This tiered approach can then ultimately be connected using mathematical models.  The DILI 
roadmap illustrates not only what can be achieved at present, but also what cannot be predicted in 
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preclinical drug development at the present time, which is critical for drug regulation and public 
education.  
A potential limitation of our strategy is that we focus predominantly on hepatocellular damage in the 
progression of events in human DILI.  There are important examples of other forms of DILI, that require 
improved in vitro models for assessment of risk, and that could be introduced into the current 
roadmap strategy. In this Perspective, we have attempted to concentrate on the earliest chemico-
biological signals that can represent perturbation in the most numerous and metabolically-active cells 
of the liver (the hepatocyte compartment) which can provide a biologically meaningful signal for 
interpretation in evaluating a range of chemical candidates.  Other cells which are the primary target 
of compounds known to cause DILI manifestations such as sinusoidal obstructive syndrome, or 
vanishing bile duct syndrome – i.e. the liver sinusoidal endothelial cell (LSEC) and the biliary epithelial 
cell – have not been specifically examined using the roadmap approach.  Nevertheless this approach 
would be feasible; there are established experimental protocols for isolation of these cells, and there 
are emerging protocols available for generating stem cell-derived LSECs and cholangiocytes191,192.  
Therefore, future work can apply the roadmap outlined here for establishing assays using these and 
indeed other non-hepatocyte liver cells and the suite of mechanistic targets discussed(e.g. 
mitochondrial stress, ER stress etc.) to assess the human relevance of these new cell models in 
screening for a range of manifestations of human DILI. 
A major gap in the present armamentarium of test systems for DILI is a model which faithfully 
recapitulates the interaction(s) of cells of hepatic origin with cells of the immune system. The advent 
of more complex multicellular systems alongside MPS technologies provides much hope for the future 
in this respect, but such systems should be used in the first instance to understand mechanisms of 
immune DILI so that their pharmacological, physiological and immunological relevance can be 
assessed before deployment in the toxicological assessment of a new drug.  Despite the many MPS 
and advanced tissue-based models currently available, few if any of these models appear fully 
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integrated as a part of the drug discovery platforms in pharmaceutical R&D27,193. Several factors can 
be attributed to slower than expected uptake in R&D, including: 
1) On-going company-specific evaluations rather than a coordinated effort across industry to unify 
on a common platform or agreed set of platforms and clear added value194,  
2) Substantial body of work required to thoroughly evaluate the physiological and pharmacological 
characteristics of these models and to assess their fidelity with fresh human-derived liver tissue195,  
3) Curated test-set and training set of compounds to permit evidence-based step-change and 
improved detection of chemical insult196 and relevance to human when compared to traditional 
2D hepatocellular-based culture models.  
4) Confidence in preclinical to clinical PK predictions, for plasma and liver, to enable concentration-
effect understanding of DILI data.  
5) Few data describing MPS responses to biologics.  
Given that the immunogenic response to NCEs in idiosyncratic DILI, and also to biologics176,197,198, 
remains a key safety challenge, future MPS systems will necessitate bioengineering and integration of 
both the innate and adaptive immune biology to study mechanisms and emulate the response in 
hypersensitivity reactions.  This must be supported by the continued development of novel safety 
biomarkers with mechanistic and translational value for use in drug discovery and clinical research199. 
Parallel valuation(s) of disease models of the liver to define changes in the safety margins of drugs in 
healthy tissue versus disease models must be performed.   
Currently, MPS and advanced models are predominantly focused on the development of platforms for 
the study of chemical insult in humanized models. However, it is similarly imperative to demonstrate 
the predictive value of MPS and advanced models through use of animal MPS models for toxicology 
to establish a translational bridge from in vitro to in vivo pre-clinically. Human-relevant test systems 
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that have been designed by retrospective analysis of DILI in humans are also needed for prospective 
risk assessment, representing a strategic pathway of “Human to molecule and back again”.  
Drug-induced liver injury in man is a function of the chemistry of the drug, the dose (mass & duration) 
and human biological variables. The roadmap provides context of use of existing test systems to 
mitigate against DILI in humans. The roadmap also provides a future guide where the continuing 
efforts must shape the distinct and focused direction of linking technologies to build-in physiologically 
relevant and pharmacologically phenotype required of in vitro systems, which not only mimic human 
exposure to drug and metabolites during therapeutic conditions but also take into account the 
spectrum of therapeutic modalities and ever-changing nature of therapeutic innovations.  
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BOX 1.  Role of dose and physico-chemical properties in the context of DILI 
Human evidence  
1. Majority of oral drugs with reported idiosyncratic liver toxicity are administered at high 
clinical doses 
2. Lipophilic drugs have higher DILI risk, explained by the increased promiscuity of high cLogP 
compounds. Carboxylic acid drugs metabolized by acyl glucuronidation have been 
associated with idiosyncratic, often liver toxicity  
Key points:  
• A low daily drug dose (<100 mg/day) is a key attribute for lower DILI risk. 
• Daily dose is a function of target potency, dose interval, and pharmacokinetic parameters  
• The “rule of two” states that a high daily dose (>100 mg/day) and lipophilicity (LogP >3) 
enhance the risk of DILI. 
• Daily dose, solubility, and lipophilicity are the three most important measures of 
compound quality from a medicinal chemistry perspective. 
• Other physico-chemical parameters useful to assess DILI risk include carbon bond 
saturation and acid/base characteristics. 
• Reactive metabolites can be risk factors for DILI due to their ability to bind cellular 
macromolecules and form adducts. 
• Computational tools are available, such as structural alerts, metabolite and toxicophore 
prediction, CYP binding and inhibition, to guide medicinal chemists and toxicologists in the 
design of safer drugs. 
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BOX 2.  Role of mitochondrial perturbation in DILI 
Human evidence  
• Retrospective analysis showed that 50% of drugs with a black-box warning for 
hepatotoxicity contained a mitochondrial liability200. 
• A PubMed search of “mitochondrial toxicity” + “drug induced liver injury” returns 332 
publications since 2013 
• Fialuridine, an example of a mitotoxicant with clear evidence in human57,201: targets 
mtDNA, localised to the mitochondria by hENT1 (human-specific).  
Application of the tiered system 
• The HepG2 glucose/galactose (glu-gal) model is based on modification of the cellular 
bioenergetic phenotype and can be used to define chemical entities, which have a direct 
effect upon mitochondrial function via the electron transport chain50,53. 
• Using the glu-gal model to simultaneously assess ATP cellular content and cell death can 
classify compounds as 1) mitochondrial toxicants and 2) mitotoxicants that lead to cell 
death. The assay can be used to screen parent compounds in TIER 1 to rank compounds 
in terms of mitotoxic liability53,54. 
• The glu-gal model is compatible with other methods to detect mitotoxicity. 
• Primary human hepatocytes lack the bioenergetic flexibility essential for differentiating 
mitotoxicity from non-mitochondrial toxicity, although they are still useful for detailed 
mechanistic studies. 
• TIER 2 mitotoxicity testing encompasses models which allow for drug interactions with 
other biological systems, including xenobiotic metabolism and biliary transport, such as 
HepaRG cells or 3D models. These also allow longer incubations with increased clinical 
relevance.  
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BOX 3. Role of transporters and bile acids (BAs) in DILI 
Human evidence  
• Hepatobiliary membrane transporters play a central role in the vectoral transport of BAs 
and secretion of cholephilic substances required for bile formation. 
• Bile canalicular membrane transporters are highly specialized proteins, which secrete bile 
salts, bilirubin glucuronides, GSH conjugates and sulfoconjugated BAs. 
• Drugs and metabolites directly and indirectly perturb hepatobiliary function, in particular 
bile canalicular function of the liver. 
• Impaired bile formation and excretion arrests bile flow, characterized by accumulation of 
BA in the liver and systemic blood202. 
• Arrest in bile flow leads to liver dysfunction, clinical cholestasis and concomitant 
hyperbilirubinemia with chronic impairment, leading to severe liver injuries including 
cirrhosis and liver failure203   
• Progressive familial intrahepatic cholestasis type 2 (PFIC-2) is caused by mutations in 
BSEP204 
Application of the tiered system 
• Hepatocellular-based models required to assess direct and indirect effects of drugs on 
hepatobiliary transporter function (TIER 1).  
• Well-characterised physiological, pharmacological and phenotypically stable cell models 
required to study drugs and metabolites on transporter function, BA uptake and efflux205 
• Key features of TIER 1 cell-models are well-formed bile canaliculi, polarized transporters 
and drug-metabolising enzymes, enabling the study of the effect of drugs and metabolites 
on BA uptake and efflux206 
• Deregulation of bile canaliculi dynamics and cellular accumulation of hydrophobic BA 
appears a unifying feature of early events in drug-induced cholestasis.  
• TIER 2 cell models would permit study of the late onset of hepatocellular dysfunction and 
toxicity, or adaptation, and help facilitate the extrapolation of mechanistic findings 
associated with hepatobiliary transport and secretion. 
• TIER 3 advanced test systems would permit the study of multicellular biological 
interactions, including role of innate and adaptive immune function on hepatobiliary BA 
transport. 
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BOX 4. The role of chemically reactive metabolites (CRM) and oxidative stress in DILI 
Human evidence: 
• Significant evidence indicates that reactive metabolites are formed from drugs known to 
cause hepatotoxicity. The best exemplar from clinical and preclinical studies is 
acetaminophen. 
• The molecular signatures of drug-induced oxidative stress have been detected in many 
test systems for many compounds, but the relevance of these signatures to liver damage 
in humans, remains to be determined. 
 
Application of the tiered system: 
 
Chemically reactive metabolites 
• Microsome-based assessment of CRM formation is a useful pre- TIER 1 chemical assay, 
although it takes no account of the crucial cellular context in which CRM are formed. 
• In TIER 1, an accurate assessment of the extent, nature and impact of CRM formation 
cannot be derived from hepatocyte cell models that have been shown to lack adequate 
CYP activity such as HepG2 and iPSC-derived differentiated hepatocytes (see Table 1). 
• If fresh PHH are unavailable, HepaRG cells, which contain significantly more CYP activity 
(particularly CYP3A4207) than more basic cell lines can be used. 
• In TIER 2, various novel cell-based models, such as 3D primary hepatocytes21 and 3D 
HepaRG cells are now being assessed to determine their metabolic competence. 
• In TIER 3, humanised animal in vivo models may be used for mechanistic investigations on 
a case-by-case basis. 
 
Oxidative stress 
• In TIER 1, ROS formation can be quantified with fluorescent probes as part of a high-
content screening strategy in simple cell systems such as HepG2 or PHH. 
• Genetically-modified HepG2 cells expressing GFP-tagged SRXN1131,132 can be used in TIER 1 
to monitor adaptive responses to oxidative stress in higher throughput using automated 
fluorescence microscopy. 
• In TIER 2, 3D models can enable more complex biological variables, such as xenobiotic 
metabolism and biliary transport, and longer incubations can be used. 
• In TIER 3, the transgenic Nrf2-luc reporter mouse135  can be used for investigations in a 
whole body context. 
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BOX 5.  Role of endoplasmic reticulum (ER) stress in DILI 
 
Human evidence? 
• Elevated ER stress markers reported in human liver cell lines (e.g. HepG2, HuH7, HepaRG), 
primary human hepatocytes and human liver slices (e.g.208) following exposure to several 
drugs, including acetaminophen, diclofenac, clozapine and efavirenz.  
• ER stress studied to a far lesser extent than other mechanisms in DILI. 
• More work is required to understand if ER stress is a direct causative mechanism for 
certain forms of human DILI, or merely a consequence of other perturbations that are 
more closely related to the mechanism of hepatotoxicity. 
Application of the tiered system 
• In tier 1, HepG2 cells can be used to examine the potential for compounds to cause ER 
stress, through measurement and imaging of components of UPR pathways131, and the 
use of UPR inhibitors to examine the effects on drug-induced toxicity. 
• In tier 2, human liver slices have been used to demonstrate an UPR response to 
hepatotoxic drugs.  
• In tier 3, western blotting and tissue staining can be used to assess the role of ER stress in 
the liver in vivo. Circulating biomarkers of the ER stress response will need to be identified 
for human translation. 
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BOX 6.  Role of the immune system in DILI  
Human evidence  
• Histological evaluation reveals innate immune cell infiltration in liver sections taken during 
transplantation or liver biopsy of patients with DILI  
• Human evidence to support the idea that the adaptive immune system is involved in DILI: 
 ○ HLA association  
 ○ Presence of T cells in liver biopsies (flucloxacillin, sulfasalazine)  
 ○ Detection of anti-drug and auto-antibodies (isoniazid)  
 ○ Isolation of drug-specific T cells (flucloxacillin, isoniazid, amoxicillin, clavulanic acid) 
Application of the tiered system 
• Currently no validated assays available in TIER 1 or TIER 2 to assess the role of the innate or 
adaptive immune system in DILI. 
• TIER 1 assays are being developed to study the release of mediators direct from the hepatocyte 
that have the potential to activate and recruit innate immune cells such as DAMPs. HepG2 GFP-
reporters for NFkB signalling (RelA and ICAM1) have been established to monitor the effect of 
compounds on disturbance of cytokine signalling172.  
• TIER 2 assays being developed allow the investigation of cell-cell communication through direct 
contact or via soluble mediators. Attempts are in progress to integrate innate immune cells 
within 2D or 3D liver microtissues. 
• Co-culture of liver cells and T cells requires an HLA-matched system. Development of stem cell 
technology to generate the different cell types from the liver is required before these assays 
can be developed. 
• In TIER 3, many mouse models use supra-physiological doses and do not mimic the features of 
DILI in man.  
• In TIER 3, in vitro T-cell assays are being developed to advance our understanding of the role of 
the adaptive immune system in DILI. Current applications include: 
 ○ Examination of drug-specific T cells in patients with DILI. These assays can be used to 
diagnose the culpable drug. 
 ○ Priming of naïve T cells. 
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Figure 1. Various chemical insults can lead to diverse clinical manifestations of DILI.  
DILI can be caused by various chemical insults (1.-5.) and present as an array of different pathologies, 
dependent on the specific function of the liver that is impaired. Furthermore, recruitment of the 
immune system (6.) can result in a prolonged or altered pathological phenotype, adding further 
complexity to the clinical presentation of the condition. 
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Figure 2. Roadmap for the development of ‘fit-for-purpose’ predictive models of human DILI  
The proposed DILI Roadmap is a tier-based testing strategy incorporating present Test Systems and 
future expectations of advanced models for DILI testing.TIER ONE comprises single cell systems that 
report on immediate chemical/biological effects such as bioactivation, drug or bile acid accumulation 
due to transporter inhibition, mitotoxicity, and signalling associated with oxidative stress, 
endoplasmic reticulum stress and inflammatory signalling. TIER TWO comprises more complex 
systems containing liver cells in a more physiologic state, enabling assessment of the consequences of 
chronic drug exposure.  TIER THREE comprises complex test systems in which a specific biological 
variable (e.g. HLA phenotype or inflammation) is introduced in a manner that can be used for both 
hazard identification and risk assessment related to idiosyncratic DILI.  Underlying this philosophy, we 
believe it to be essential that the pharmacological and physiological phenotype of the test system is 
considered (Phenotype → Functions), before undertaking toxicological investigations, to ensure that 
the most appropriate methods are used to determine the potential DILI liability of a new drug.  To 
integrate findings from different test systems and to dissect the multi-level impact of compounds, 
mathematical models will also be useful.  
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Figure 3.  Hepatocyte couplet illustrating the basolateral and canalicular location of transport 
proteins. Bile acids (BAs): Unconjugated BA species (BA); monovalent BA (mBA), BA-G 
(glucuronidated BAs); BA-S (Sulpho and sulpho-conjugated BAs). Examples of different classes of 
drug substrates (blue), inhibitors (red) and inducers (purple) across multiple transporters are given. 
Some drugs are both substrates and inhibitors of transporter proteins depending on the affinity of 
respective drugs. Selectivity of transporters for the different monovalent, divalent and conjugated 
forms of BAs (green) across the basolateral and apical membranes illustrates the multiplicity of 
transporters involved in bile uptake and efflux. The heterodimeric organic solute transporter 
OSTα/OSTβ an efflux transporter, but also bidirectional transporter for some organic anions. Some 
amphiphilic BAs passively diffuse across the basolateral membrane. Phosphatidylcholine (PC) is a 
physiologically important substrate for MDR3 and its inhibition may play an important role in 
cholestasis and vanishing bile duct syndrome (VBDS). The role of taurocholic acid (TCA) in micelles 
has an important role on MDR3 activity. See supplementary information for transporter protein 
homology, function and drug interactions.  
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Figure 4. The role of the adaptive immune system in drug-induced liver injury 
(A) Several thousand HLA allelic variants encode human MHC molecules. MHC molecules expressed 
on the surface of antigen-presenting cells are responsible for presentation of processed peptides to 
T-cells. Several forms of drug-induced liver injury have been shown to be strongly associated with 
expression of a single HLA. To activate T-cells, the drug must associate MHC molecules expressed on 
the surface of antigen-presenting cells, the peptide bound to within the MHC peptide-binding 
groove and T-cell receptors. To do this, drugs bind directly via a labile readily reversible interaction. 
Alternatively, drugs and drug metabolites act as haptens and bind covalently to protein. The 
resultant adduct is taken up by antigen-presenting cells and processed. The derived peptides then 
associate with MHC class I or II molecules for presentation to CD8+ and CD4+ T-cells, respectively 
(signal 1). Antigen-presenting cells receive stress signals from damaged tissue. This leads to altered 
expression of co-stimulatory and/or co-inhibitory receptors that interact with cognate receptors on 
T-cells to control the nature of the drug-specific response (signal 2). T-cells displaying reactivity to 
several DILI drugs have recently been isolated from PBMCs of patients with liver injury, but not 
tolerant controls. Furthermore, drug-specific T-cells can kill hepatocyte-like cells expressing the MHC 
molecule for drug presentation.  
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TABLES 
Table 1: Relative advantages and disadvantages of the most popular single cell hepatocyte models 
for industry DILI assessment, including their position in the proposed tiered testing system 
Cell Type/Tier Advantages  Disadvantages  
HepG2/TIER 1 Human hepatic origin.  
Easy to culture.   
Inexpensive.   
Consistent, reproducible, fast turnaround 
assay performance for the toxicological 
endpoint under investigation.   
No donor variation.   
Easily adaptable for specific assays – e.g. 
mitotoxicity assay, high-content screening. 
Can be cultured in 3D.  
Large, publicly-available datasets for 
cytotoxicity & gene expression assists risk 
assessment. Popular for use in HTS approaches 
and toxigenomics 
Cancer-derived.  
Many clonal variants exist with 
different cellular characteristics.  
Relative lack in expression of 
drug metabolizing enzymes and 
transporters. Majority of genes 
expressed in HepG2 cells are also 
expressed in primary 
hepatocytes, yet 30% of the gene 
expression profiles are unique to 
HepG2209. 
HepaRG/ 
TIER 1 or TIER 2 
Human hepatic origin. Relatively 
straightforward to culture.   
More consistent than primary hepatocytes.   
Cancer cell.   
More costly and time-
consuming to culture than 
HepG2.  
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Some defined Phase 1 activity (especially P450-
3A4). After exposure to CYP inducers CYP450s 
and transporter protein activities are induced 
making them amenable for the studies of 
ADMET mechanisms and use of gene 
expression profiles209,210.  Functional bile 
canaliculi.  
Can be cultured in 3D. 
Requires proprietary media for 
stable phenotype 
Human Primary 
Hepatocytes 
 
TIER 1 or TIER 2 
The closest approximation to a liver-resident 
hepatocyte.  More metabolic activity than any 
other liver cell model in short term cultures.  
Can be cultured in 3D. Donor-dependent 
metabolic phenotype allows refined risk 
assessment. 
Loses metabolic activity rapidly 
during culture.  Variability in 
phenotype between donors. 
Greater cost vs cell lines. 
Exhaustible cell supply.  
Stem cell-
derived 
hepatocytes / 
hepatocyte-like 
cells/ 
 
TIER 2 
Reproduces many  hepatocyte functions  
Possibility of deriving hepatocyte-like cells and 
other liver cell types from the same human 
donor  
Patient specific genotype/phenotype (e.g. 
derived from DILI patients).   No need to isolate 
liver tissue per se.   
Large-scale investment in this area.  
Expensive 
Not as reproducible as other 
liver cell models 
Relative cell immaturity  
Lack of available robust 
differentiation protocols 
available – different protocols 
led to high variations in 
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transformed hepatocyte like 
cells 
Requires further 
characterisation/ validation  
Liver slices Maintains the architecture and 
microenvironment (cell-cell interactions) of 
fresh tissue and therefore highly relevant to 
the in vivo situation.  
Good correlates of ex vivo transcriptomic 
profiles with in vivo tissue. Coordinated 
regulation of CYP and transporter proteins in 
human tissue211. Liver function test remain 
stable211,212. Recent technology developments 
permit maintenance for 6-days213. 
Expression of CYP enzymes 
remains stable for only 24h.  
Limited availability of human 
fresh tissue. 
Not amenable for HTS drug 
screening.  
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